Advertisement
Advertisement
SABS
SAB Biotherapeutics, Inc. Common Stock
3.88
USDSponsored
+0.01
+0.26%
Jun 24, 14:38 UTC -4
Open
SABS Earnings Reports
Positive Surprise Ratio
SABS beat 11 of 19 last estimates.
58%
Next Report
Date of Next Report
Aug 05, 2026
Estimate for Q2 26 (Revenue/ EPS)
--
/-$0.28
Implied change from Q1 26 (Revenue/ EPS)
--
/-20.00%
Implied change from Q2 25 (Revenue/ EPS)
--
/-74.31%
SAB Biotherapeutics, Inc. Common Stock earnings per share and revenue
On May 12, 2026, SABS reported earnings of -0.35 USD per share (EPS) for Q1 26, missing the estimate of -0.23 USD, resulting in a -50.28% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a -2.69% price change (close before vs. close after earnings).
Looking ahead to Q2 26, 8 analysts forecast an EPS of -0.28 USD, with revenue projected to reach -- USD, implying an decrease of -20.00% EPS, and increase of 0.00% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
enGene Therapeutics Inc. Common Stock
Report Date
Jun 15, 2026 For Q2 26
Estimate
-$0.47
Actual
-$0.43
Surprise
+10.32%
Prenetics Global Limited Class A Ordinary Share
Report Date
Jun 10, 2026 For Q1 26
Estimate
-$1.10
Actual
-$1.61
Surprise
-45.36%
Anixa Biosciences, Inc.
Report Date
Jun 10, 2026 For Q2 26
Estimate
-$0.08
Actual
-$0.07
Surprise
+21.61%
Vistagen Therapeutics, Inc. Common Stock
Report Date
Jun 15, 2026 For Q4 26
Estimate
-$0.34
Actual
-$0.37
Surprise
-7.75%
FAQ
What were SAB Biotherapeutics, Inc. Common Stock's earnings and revenue for the latest quarter Q1 2026?
For Q1 2026, SAB Biotherapeutics, Inc. Common Stock reported EPS of -$0.35, missing estimates by -50.28%, and revenue of $0.00, 0% as expectations.
How did the market react to SAB Biotherapeutics, Inc. Common Stock's Q1 2026 earnings?
The stock price moved down -2.69%, changed from $3.72 before the earnings release to $3.62 the day after.
When is SAB Biotherapeutics, Inc. Common Stock expected to report next?
The next earning report is scheduled for Aug 05, 2026.
What are the forecasts for SAB Biotherapeutics, Inc. Common Stock's next earnings report?
Based on 8
analysts, SAB Biotherapeutics, Inc. Common Stock is expected to report EPS of -$0.28 and revenue of -- for Q2 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement